CY1115453T1 - Φαρμακευτικη συνθεση που περιλαμβανει ενα ανασταλτικο παραγοντα του ενζυμου ημg-cοα αναγαγασης και ενα ανασταλτικο παραγοντα του ενζυμου γαστρεντερικης λιπασης - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει ενα ανασταλτικο παραγοντα του ενζυμου ημg-cοα αναγαγασης και ενα ανασταλτικο παραγοντα του ενζυμου γαστρεντερικης λιπασης

Info

Publication number
CY1115453T1
CY1115453T1 CY20141100617T CY141100617T CY1115453T1 CY 1115453 T1 CY1115453 T1 CY 1115453T1 CY 20141100617 T CY20141100617 T CY 20141100617T CY 141100617 T CY141100617 T CY 141100617T CY 1115453 T1 CY1115453 T1 CY 1115453T1
Authority
CY
Cyprus
Prior art keywords
analytical
pharmaceutical composition
coaga
enzyming
emg
Prior art date
Application number
CY20141100617T
Other languages
English (en)
Inventor
Armenta María Elena García
Murillo Josefina Santos
Ochoa Victor Guillermo Alvarez
Original Assignee
Pptm International S.À R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pptm International S.À R.L. filed Critical Pptm International S.À R.L.
Publication of CY1115453T1 publication Critical patent/CY1115453T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μια φαρμακευτική σύνθεση που περιλαμβάνει ένα συνεργικό συνδυασμό ενός ανασταλτικού παράγοντα του ενζύμου HMG-CoA αναγαγάσης, όπως η δραστική ουσία ατορβαστατίνη και ένα ανασταλτικό παράγοντα του ενζύμου γαστρεντερικής λιπάσης, όπως η δραστική ουσία ορλιστάνη, που τυποποιούνται σε μια ενιαία μονάδα δοσολογίας που πρόκειται να χορηγείται δια του στόματος για θεραπεία και έλεγχο ασθενειών όπως οι δυσλιπιδαιμίες (υπερχοληστερολαιμία και υπερτριγλυκεριδιαμία) και άλλων σχετικών καταστάσεων.
CY20141100617T 2007-06-15 2014-08-07 Φαρμακευτικη συνθεση που περιλαμβανει ενα ανασταλτικο παραγοντα του ενζυμου ημg-cοα αναγαγασης και ενα ανασταλτικο παραγοντα του ενζυμου γαστρεντερικης λιπασης CY1115453T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007007283A MX2007007283A (es) 2007-06-15 2007-06-15 Composicion farmaceutica que comprende la combinacion de un agente inhibidor de la enzima hmg-coa reductasa y un agente inhibidor de la enzima lipasa gastrointestinal.
EP08778967.3A EP2179732B1 (en) 2007-06-15 2008-06-16 Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent

Publications (1)

Publication Number Publication Date
CY1115453T1 true CY1115453T1 (el) 2017-01-04

Family

ID=40129898

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100617T CY1115453T1 (el) 2007-06-15 2014-08-07 Φαρμακευτικη συνθεση που περιλαμβανει ενα ανασταλτικο παραγοντα του ενζυμου ημg-cοα αναγαγασης και ενα ανασταλτικο παραγοντα του ενζυμου γαστρεντερικης λιπασης

Country Status (11)

Country Link
EP (1) EP2179732B1 (el)
AR (1) AR067038A1 (el)
BR (1) BRPI0813174A2 (el)
CO (1) CO6241106A2 (el)
CY (1) CY1115453T1 (el)
EC (1) ECSP099801A (el)
ES (1) ES2492665T3 (el)
GT (1) GT200900316A (el)
MX (1) MX2007007283A (el)
PL (1) PL2179732T3 (el)
WO (1) WO2008153374A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314232A (zh) * 2019-08-03 2019-10-11 黄泳华 由脂肪酶抑制剂与羟甲戊二酰辅酶a还原酶抑制剂构成的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
WO2006109170A2 (en) * 2005-04-14 2006-10-19 Esperion Therapeutics Inc. Combination therapy for treatment of cardiovascular diseases and related conditions
MXPA06010973A (es) * 2006-09-25 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia.

Also Published As

Publication number Publication date
WO2008153374A8 (es) 2010-02-04
MX2007007283A (es) 2009-02-18
EP2179732A4 (en) 2010-08-25
GT200900316A (es) 2011-07-25
EP2179732B1 (en) 2014-05-14
ECSP099801A (es) 2010-01-29
CO6241106A2 (es) 2011-01-20
EP2179732A1 (en) 2010-04-28
BRPI0813174A2 (pt) 2014-12-23
ES2492665T3 (es) 2014-09-10
AR067038A1 (es) 2009-09-30
PL2179732T3 (pl) 2014-10-31
WO2008153374A1 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200900959A1 (ru) Ингибиторы мек
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
EA201270546A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
ATE510821T1 (de) Sulfonylpyrrole als histondeacetylaseinhibitoren
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2007128086A3 (en) Novel viral replication inhibitor
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern